Alcoholic Hepatitis Treatment Market
Description
Alcoholic Hepatitis Treatment Market
The alcoholic hepatitis treatment market was valued at $668.44 million in 2024 and is estimated to reach $1,064.98 million by 2034, exhibiting a CAGR of 4.7% from 2025 to 2034.
Alcoholic hepatitis is a severe and potentially life-threatening inflammatory liver condition caused by excessive alcohol consumption. It is characterized by symptoms such as jaundice, liver enlargement, and liver failure in advanced stages. Treatment typically involves lifestyle modifications, corticosteroids, nutritional therapy, and in some cases, liver transplantation. With increase in global prevalence of alcohol abuse and liver-related disorders, the alcoholic hepatitis treatment market is witnessing gradual growth. The market comprises pharmaceuticals, biologics, and supportive therapies aimed at managing symptoms and halting disease progression.
Rise in incidence of alcohol use disorder (AUD) globally and surge in awareness about liver-related health conditions significantly drive the growth of the alcoholic hepatitis treatment market. In addition, increase in burden of liver cirrhosis and related complications fuels the demand for more effective treatment options. The introduction of new clinical guidelines and government-backed awareness programs boosts early diagnosis and therapeutic intervention. Furthermore, ongoing R&D activities and advancements in drug development, especially involving anti-inflammatory and immune-modulating agents, are expected to accelerate market growth.
However, several restraints hinder the expansion of the alcoholic hepatitis treatment market. These include the limited availability of targeted treatment options and the poor efficacy of existing therapies such as corticosteroids, which are not effective in all patients. In addition, the social stigma associated with alcohol-related diseases, lack of adherence to treatment, and high cost of advanced therapies such as liver transplantation pose significant challenges. Moreover, limited clinical trial data and a slow drug approval process further delay the development of innovative solutions.
On the other hand, increase in investment in liver disease research, particularly in biologics and regenerative therapies, holds promise for more effective and personalized treatments. The development of novel drug delivery systems and biomarkers for early diagnosis could improve therapeutic outcomes. In addition, public-private partnerships and the expansion of healthcare infrastructure in emerging economies are expected to enhance access to care. Collaborations between biotech firms and academic institutions drive innovation, creating new opportunities for market players in the coming years. For instance, in 2023, Teva Pharmaceutical Industries Ltd. launched a generic version of Votrient (pazopanib hydrochloride) tablets, a treatment for renal cell carcinoma and soft tissue sarcoma.
Segment Review
The alcoholic hepatitis treatment market is segmented into treatment, route of administration, distribution channel, and region. By treatment, the market is segregated into corticosteroids, hemorroheologic agents, and others. By route of administration, the market is categorized into oral and injectable. By distribution channel, the market is classified into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and Rest of LAMEA).
Key Findings:
By treatment, the corticosteroids segment dominated the market share in 2024.
On the basis of route of administration, the oral segment accounted for the largest share in 2024.
On the basis of distribution channel, the drug stores and retail pharmacies segment accounted for the largest share in 2024.
Region-wise, North America generated the highest revenue in 2024.
Competition Analysis
Major players that operate in the alcoholic hepatitis treatment market are ANI Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Pfizer Inc., Viatris Inc., Advacare Pharma Inc., Aurobindo Pharma, Cumberland Pharmaceuticals Inc., Taj Pharma Group, Apotex Inc., and Sun Pharmaceutical Industries Ltd. Key players have adopted product approval and product launch as key developmental strategies to improve the product portfolio of the alcoholic hepatitis treatment market.
Key Market Segments
By Route of Administration
Oral
Injectable
By Treatment
Corticosteroids
Hemorroheologic Agents
Others
By Distribution Channel
Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Providers
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
ANI Pharmaceuticals, Inc.
Pfizer Inc.
Viatris Inc.
Aurobindo Pharma
Cumberland Pharmaceuticals Inc.
Apotex Inc.
Teva Pharmaceutical Industries Ltd.
Advacare Pharma Inc.
Taj Pharma Group
Sun Pharmaceutical Industries Ltd.The research methodology of the global market involves extensive primary and secondary research. Primary research includes about over 12 hours of interviews and discussion with a wide range of stakeholders, including upstream and downstream participants. The primary research typically is the bulk of our research efforts; however, coherently supported by extensive secondary research. Researchers have reviewed over 6,765 product literatures, industry releases, annual reports, and other such documents of key industry participants to obtain better market understanding and gain competitive intelligence. In addition, authentic industry journals, trade associations' releases,and government websites have also been reviewed for generating high-value industry insights.
The alcoholic hepatitis treatment market was valued at $668.44 million in 2024 and is estimated to reach $1,064.98 million by 2034, exhibiting a CAGR of 4.7% from 2025 to 2034.
Alcoholic hepatitis is a severe and potentially life-threatening inflammatory liver condition caused by excessive alcohol consumption. It is characterized by symptoms such as jaundice, liver enlargement, and liver failure in advanced stages. Treatment typically involves lifestyle modifications, corticosteroids, nutritional therapy, and in some cases, liver transplantation. With increase in global prevalence of alcohol abuse and liver-related disorders, the alcoholic hepatitis treatment market is witnessing gradual growth. The market comprises pharmaceuticals, biologics, and supportive therapies aimed at managing symptoms and halting disease progression.
Rise in incidence of alcohol use disorder (AUD) globally and surge in awareness about liver-related health conditions significantly drive the growth of the alcoholic hepatitis treatment market. In addition, increase in burden of liver cirrhosis and related complications fuels the demand for more effective treatment options. The introduction of new clinical guidelines and government-backed awareness programs boosts early diagnosis and therapeutic intervention. Furthermore, ongoing R&D activities and advancements in drug development, especially involving anti-inflammatory and immune-modulating agents, are expected to accelerate market growth.
However, several restraints hinder the expansion of the alcoholic hepatitis treatment market. These include the limited availability of targeted treatment options and the poor efficacy of existing therapies such as corticosteroids, which are not effective in all patients. In addition, the social stigma associated with alcohol-related diseases, lack of adherence to treatment, and high cost of advanced therapies such as liver transplantation pose significant challenges. Moreover, limited clinical trial data and a slow drug approval process further delay the development of innovative solutions.
On the other hand, increase in investment in liver disease research, particularly in biologics and regenerative therapies, holds promise for more effective and personalized treatments. The development of novel drug delivery systems and biomarkers for early diagnosis could improve therapeutic outcomes. In addition, public-private partnerships and the expansion of healthcare infrastructure in emerging economies are expected to enhance access to care. Collaborations between biotech firms and academic institutions drive innovation, creating new opportunities for market players in the coming years. For instance, in 2023, Teva Pharmaceutical Industries Ltd. launched a generic version of Votrient (pazopanib hydrochloride) tablets, a treatment for renal cell carcinoma and soft tissue sarcoma.
Segment Review
The alcoholic hepatitis treatment market is segmented into treatment, route of administration, distribution channel, and region. By treatment, the market is segregated into corticosteroids, hemorroheologic agents, and others. By route of administration, the market is categorized into oral and injectable. By distribution channel, the market is classified into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and Rest of LAMEA).
Key Findings:
By treatment, the corticosteroids segment dominated the market share in 2024.
On the basis of route of administration, the oral segment accounted for the largest share in 2024.
On the basis of distribution channel, the drug stores and retail pharmacies segment accounted for the largest share in 2024.
Region-wise, North America generated the highest revenue in 2024.
Competition Analysis
Major players that operate in the alcoholic hepatitis treatment market are ANI Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Pfizer Inc., Viatris Inc., Advacare Pharma Inc., Aurobindo Pharma, Cumberland Pharmaceuticals Inc., Taj Pharma Group, Apotex Inc., and Sun Pharmaceutical Industries Ltd. Key players have adopted product approval and product launch as key developmental strategies to improve the product portfolio of the alcoholic hepatitis treatment market.
Key Market Segments
By Route of Administration
Oral
Injectable
By Treatment
Corticosteroids
Hemorroheologic Agents
Others
By Distribution Channel
Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Providers
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
ANI Pharmaceuticals, Inc.
Pfizer Inc.
Viatris Inc.
Aurobindo Pharma
Cumberland Pharmaceuticals Inc.
Apotex Inc.
Teva Pharmaceutical Industries Ltd.
Advacare Pharma Inc.
Taj Pharma Group
Sun Pharmaceutical Industries Ltd.The research methodology of the global market involves extensive primary and secondary research. Primary research includes about over 12 hours of interviews and discussion with a wide range of stakeholders, including upstream and downstream participants. The primary research typically is the bulk of our research efforts; however, coherently supported by extensive secondary research. Researchers have reviewed over 6,765 product literatures, industry releases, annual reports, and other such documents of key industry participants to obtain better market understanding and gain competitive intelligence. In addition, authentic industry journals, trade associations' releases,and government websites have also been reviewed for generating high-value industry insights.
Table of Contents
299 Pages
- CHAPTER 1: INTRODUCTION
- 1.1. Report description
- 1.2. Key market segments
- 1.3. Key benefits to the stakeholders
- 1.4. Research methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models
- CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO perspective
- CHAPTER 3: MARKET OVERVIEW
- 3.1. Market definition and scope
- 3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
- 3.3. Porter’s five forces analysis
- 3.3.1. Moderate bargaining power of suppliers
- 3.3.2. Moderate threat of new entrants
- 3.3.3. Moderate threat of substitutes
- 3.3.4. Moderate intensity of rivalry
- 3.3.5. Moderate bargaining power of buyers
- 3.4. Market dynamics
- 3.4.1. Drivers
- 3.4.1.1. Rise in prevalence of alcohol-related liver diseases
- 3.4.1.2. Increase in research funding
- 3.4.1.3. Growing awareness and early diagnosis
- 3.4.2. Restraints
- 3.4.2.1. Limited approved treatment options
- 3.4.3. Opportunities
- 3.4.3.1. Expanding clinical trials and research initiatives
- CHAPTER 4: ALCOHOLIC HEPATITIS TREATMENT MARKET, BY TREATMENT
- 4.1. Overview
- 4.1.1. Market size and forecast
- 4.2. Corticosteroids
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
- 4.3. Hemorroheologic Agents
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
- 4.4. Others
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country
- CHAPTER 5: ALCOHOLIC HEPATITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
- 5.1. Overview
- 5.1.1. Market size and forecast
- 5.2. Oral
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
- 5.3. Injectable
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
- CHAPTER 6: ALCOHOLIC HEPATITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
- 6.1. Overview
- 6.1.1. Market size and forecast
- 6.2. Hospital Pharmacies
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
- 6.3. Drug Stores and Retail Pharmacies
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
- 6.4. Online Providers
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country
- CHAPTER 7: ALCOHOLIC HEPATITIS TREATMENT MARKET, BY REGION
- 7.1. Overview
- 7.1.1. Market size and forecast By Region
- 7.2. North America
- 7.2.1. Key market trends, growth factors and opportunities
- 7.2.2. Market size and forecast, by Treatment
- 7.2.3. Market size and forecast, by Route of Administration
- 7.2.4. Market size and forecast, by Distribution Channel
- 7.2.5. Market size and forecast, by country
- 7.2.5.1. U.S.
- 7.2.5.1.1. Market size and forecast, by Treatment
- 7.2.5.1.2. Market size and forecast, by Route of Administration
- 7.2.5.1.3. Market size and forecast, by Distribution Channel
- 7.2.5.2. Canada
- 7.2.5.2.1. Market size and forecast, by Treatment
- 7.2.5.2.2. Market size and forecast, by Route of Administration
- 7.2.5.2.3. Market size and forecast, by Distribution Channel
- 7.2.5.3. Mexico
- 7.2.5.3.1. Market size and forecast, by Treatment
- 7.2.5.3.2. Market size and forecast, by Route of Administration
- 7.2.5.3.3. Market size and forecast, by Distribution Channel
- 7.3. Europe
- 7.3.1. Key market trends, growth factors and opportunities
- 7.3.2. Market size and forecast, by Treatment
- 7.3.3. Market size and forecast, by Route of Administration
- 7.3.4. Market size and forecast, by Distribution Channel
- 7.3.5. Market size and forecast, by country
- 7.3.5.1. Germany
- 7.3.5.1.1. Market size and forecast, by Treatment
- 7.3.5.1.2. Market size and forecast, by Route of Administration
- 7.3.5.1.3. Market size and forecast, by Distribution Channel
- 7.3.5.2. France
- 7.3.5.2.1. Market size and forecast, by Treatment
- 7.3.5.2.2. Market size and forecast, by Route of Administration
- 7.3.5.2.3. Market size and forecast, by Distribution Channel
- 7.3.5.3. UK
- 7.3.5.3.1. Market size and forecast, by Treatment
- 7.3.5.3.2. Market size and forecast, by Route of Administration
- 7.3.5.3.3. Market size and forecast, by Distribution Channel
- 7.3.5.4. Italy
- 7.3.5.4.1. Market size and forecast, by Treatment
- 7.3.5.4.2. Market size and forecast, by Route of Administration
- 7.3.5.4.3. Market size and forecast, by Distribution Channel
- 7.3.5.5. Spain
- 7.3.5.5.1. Market size and forecast, by Treatment
- 7.3.5.5.2. Market size and forecast, by Route of Administration
- 7.3.5.5.3. Market size and forecast, by Distribution Channel
- 7.3.5.6. Rest of Europe
- 7.3.5.6.1. Market size and forecast, by Treatment
- 7.3.5.6.2. Market size and forecast, by Route of Administration
- 7.3.5.6.3. Market size and forecast, by Distribution Channel
- 7.4. Asia-Pacific
- 7.4.1. Key market trends, growth factors and opportunities
- 7.4.2. Market size and forecast, by Treatment
- 7.4.3. Market size and forecast, by Route of Administration
- 7.4.4. Market size and forecast, by Distribution Channel
- 7.4.5. Market size and forecast, by country
- 7.4.5.1. Japan
- 7.4.5.1.1. Market size and forecast, by Treatment
- 7.4.5.1.2. Market size and forecast, by Route of Administration
- 7.4.5.1.3. Market size and forecast, by Distribution Channel
- 7.4.5.2. China
- 7.4.5.2.1. Market size and forecast, by Treatment
- 7.4.5.2.2. Market size and forecast, by Route of Administration
- 7.4.5.2.3. Market size and forecast, by Distribution Channel
- 7.4.5.3. India
- 7.4.5.3.1. Market size and forecast, by Treatment
- 7.4.5.3.2. Market size and forecast, by Route of Administration
- 7.4.5.3.3. Market size and forecast, by Distribution Channel
- 7.4.5.4. Australia
- 7.4.5.4.1. Market size and forecast, by Treatment
- 7.4.5.4.2. Market size and forecast, by Route of Administration
- 7.4.5.4.3. Market size and forecast, by Distribution Channel
- 7.4.5.5. South Korea
- 7.4.5.5.1. Market size and forecast, by Treatment
- 7.4.5.5.2. Market size and forecast, by Route of Administration
- 7.4.5.5.3. Market size and forecast, by Distribution Channel
- 7.4.5.6. Rest of Asia-Pacific
- 7.4.5.6.1. Market size and forecast, by Treatment
- 7.4.5.6.2. Market size and forecast, by Route of Administration
- 7.4.5.6.3. Market size and forecast, by Distribution Channel
- 7.5. LAMEA
- 7.5.1. Key market trends, growth factors and opportunities
- 7.5.2. Market size and forecast, by Treatment
- 7.5.3. Market size and forecast, by Route of Administration
- 7.5.4. Market size and forecast, by Distribution Channel
- 7.5.5. Market size and forecast, by country
- 7.5.5.1. Brazil
- 7.5.5.1.1. Market size and forecast, by Treatment
- 7.5.5.1.2. Market size and forecast, by Route of Administration
- 7.5.5.1.3. Market size and forecast, by Distribution Channel
- 7.5.5.2. Saudi Arabia
- 7.5.5.2.1. Market size and forecast, by Treatment
- 7.5.5.2.2. Market size and forecast, by Route of Administration
- 7.5.5.2.3. Market size and forecast, by Distribution Channel
- 7.5.5.3. South Africa
- 7.5.5.3.1. Market size and forecast, by Treatment
- 7.5.5.3.2. Market size and forecast, by Route of Administration
- 7.5.5.3.3. Market size and forecast, by Distribution Channel
- 7.5.5.4. Rest of LAMEA
- 7.5.5.4.1. Market size and forecast, by Treatment
- 7.5.5.4.2. Market size and forecast, by Route of Administration
- 7.5.5.4.3. Market size and forecast, by Distribution Channel
- CHAPTER 8: COMPETITIVE LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product mapping of top 10 player
- 8.4. Competitive dashboard
- 8.5. Competitive heatmap
- 8.6. Top player positioning, 2024
- CHAPTER 9: COMPANY PROFILES
- 9.1. Teva Pharmaceutical Industries Ltd.
- 9.1.1. Company overview
- 9.1.2. Key executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
- 9.2. ANI Pharmaceuticals, Inc.
- 9.2.1. Company overview
- 9.2.2. Key executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
- 9.2.7. Key strategic moves and developments
- 9.3. Cumberland Pharmaceuticals Inc.
- 9.3.1. Company overview
- 9.3.2. Key executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
- 9.3.7. Key strategic moves and developments
- 9.4. Taj Pharma Group
- 9.4.1. Company overview
- 9.4.2. Key executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.5. Pfizer Inc.
- 9.5.1. Company overview
- 9.5.2. Key executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
- 9.6. Viatris Inc.
- 9.6.1. Company overview
- 9.6.2. Key executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
- 9.7. Advacare Pharma Inc.
- 9.7.1. Company overview
- 9.7.2. Key executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.8. Aurobindo Pharma
- 9.8.1. Company overview
- 9.8.2. Key executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
- 9.9. Apotex Inc.
- 9.9.1. Company overview
- 9.9.2. Key executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.10. Sun Pharmaceutical Industries Ltd.
- 9.10.1. Company overview
- 9.10.2. Key executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
